Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HCW Biologics Inc.HCWB · Entity 8172 | Director · Chief Executive Officer · 10% owner | July 29, 2026 | July 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HCW Biologics Inc.
Report date July 29, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 125,845 |
Reported balance
After 2026-07-29 transaction · row 1
1 source rowRow 1 · 2026-07-29 · Purchase · Acquired 23,210 · Balance 125,845 F1: The reporting person purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026 ("SPA"), which purchase is exempt from the registration requirements of Section 5 of the Securities Exchange Act of 1934, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder. Additionally, the reporting person is entitled to receive common warrants exercisable for an aggregate of up to 23,210 shares of common stock. Under the terms of the SPA, issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Upon issuance, the common warrants will be exercisable immediately and expire 5.5 years from date of issuance. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026 ("SPA"), which purchase is exempt from the registration requirements of Section 5 of the Securities Exchange Act of 1934, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder. Additionally, the reporting person is entitled to receive common warrants exercisable for an aggregate of up to 23,210 shares of common stock. Under the terms of the SPA, issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Upon issuance, the common warrants will be exercisable immediately and expire 5.5 years from date of issuance.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2026 Filed Jul 31, 2026 20:10 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 23,210 | $2.59 | $59,997.85 |
DisclosureSEC source: 0001493152-26-035634 · ownership.xml · nonDerivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,845 F1 · kind: The reporting person purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026 ("SPA"), which purchase is exempt from the registration requirements of Section 5 of the Securities Exchange Act of 1934, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder. Additionally, the reporting person is entitled to receive common warrants exercisable for an aggregate of up to 23,210 shares of common stock. Under the terms of the SPA, issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Upon issuance, the common warrants will be exercisable immediately and expire 5.5 years from date of issuance. Read SEC document |
| May 22, 2026 Filed May 27, 2026 23:26 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock Purchase Warrant · Derivative | 113,879 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001493152-26-025478 · ownership.xml · derivative · entry 2 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,110 Underlying: Common Stock · 113,879 shares Expires 2031-11-22 F1 · kind: The reporting person purchased these shares directly from the issuer in a private placement, which purchase is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 22, 2026 Filed May 27, 2026 23:26 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 113,879 | $1.41 | $160,000.00 |
DisclosureSEC source: 0001493152-26-025478 · ownership.xml · nonDerivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 615,790 F1 · kind: The reporting person purchased these shares directly from the issuer in a private placement, which purchase is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:35 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 8,054 | $7.45 | $60,002.30 |
DisclosureSEC source: 0000950170-25-075259 · ownership.xml · nonDerivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 501,911 F1 · shares: These shares were issued pursuant to a conversion of Unsecured Convertible Promissory Notes which were issued to six holders through a Company financing of an aggregate principal of $270,000 in one-year Notes. The Notes contained a mandatory conversion provision, which resulted in the Notes converting into shares of common stock at a mandatory conversion price of $7.45 per share as set by the registered offering. The Notes converted after the closing of the Company's registered offering on May 15, 2025. The conversion transaction also included an allocated portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company. Read SEC document |
| May 08, 2025 Filed May 9, 2025 21:32 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 92,500 | $26.00 | $2,405,000.00 |
DisclosureSEC source: 0000950170-25-068292 · ownership.xml · nonDerivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 493,857 F1 · kind: These shares are being issued as a portion of and pursuant to the Company entering into a definitive conversion agreement on May 1, 2025, with a conversion date of May 7, 2025, along with 13 other holders of $6.6 million of the outstanding principal of the Secured Notes to convert the Secured Notes for an aggregate of 253,083 shares of the Company's Common Stock at a conversion price of $26.00 per share (on a post-reverse split basis), issuance of an aggregate of 126,540 warrants each exercisable for one share of Common Stock at an exercise price of $26.00 per share (on a post-reverse split basis), and a portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company. Read SEC document |
| May 07, 2025 Filed May 9, 2025 21:32 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock Purchase Warrant · Derivative | 46,250 | $0.00 Strike: $26.00 | $0.00 |
DisclosureSEC source: 0000950170-25-068292 · ownership.xml · derivative · entry 2 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,250 Underlying: Common Stock · 46,250 shares Expires 2030-05-07 F1 · kind: These shares are being issued as a portion of and pursuant to the Company entering into a definitive conversion agreement on May 1, 2025, with a conversion date of May 7, 2025, along with 13 other holders of $6.6 million of the outstanding principal of the Secured Notes to convert the Secured Notes for an aggregate of 253,083 shares of the Company's Common Stock at a conversion price of $26.00 per share (on a post-reverse split basis), issuance of an aggregate of 126,540 warrants each exercisable for one share of Common Stock at an exercise price of $26.00 per share (on a post-reverse split basis), and a portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 19:24 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantCommon Stock | 739,288 | $1.40 | $1,035,003.20 |
DisclosureSEC source: 0001209191-24-003787 · doc4.xml · nonDerivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,054,156 F1 · kind: The reporting person purchased these shares directly from the issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 20:36 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 1,800 | $2.08 | $3,740.76 |
DisclosureSEC source: 0001209191-23-049774 · doc4.xml · nonDerivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,314,868 F1 · price: The range of prices for the shares of Common Stock is from $2.0536 to $2.1109. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| June 02, 2023 Filed Jun 3, 2023 00:25 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 800 | $1.54 | $1,228.24 |
DisclosureSEC source: 0001209191-23-034098 · doc4.xml · nonDerivative · entry 2 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,313,068 F2 · price: The range of prices for the shares of Common Stock is from $1.5045 to $1.5666. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| June 01, 2023 Filed Jun 3, 2023 00:25 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 800 | $1.62 | $1,294.24 |
DisclosureSEC source: 0001209191-23-034098 · doc4.xml · nonDerivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,312,268 F1 · price: The range of prices for the shares of Common Stock is from $1.60 to $1.6311. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 21:47 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 2,000 | $1.55 | $3,092.00 |
DisclosureSEC source: 0001209191-23-033397 · doc4.xml · nonDerivative · entry 2 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,311,468 F2 · price: The range of prices for the shares of Common Stock is from $1.5148 to $1.5675. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 21:47 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 3,000 | $1.55 | $4,658.10 |
DisclosureSEC source: 0001209191-23-033397 · doc4.xml · nonDerivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,309,468 F1 · price: The range of prices for the shares of Common Stock is from $1.4944 to $1.6403. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 19:05 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 6,000 | $2.70 | $16,200.00 |
DisclosureSEC source: 0001209191-22-049469 · doc4.xml · nonDerivative · entry 2 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,306,468 Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 19:05 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 4,000 | $2.67 | $10,680.00 |
DisclosureSEC source: 0001209191-22-049469 · doc4.xml · nonDerivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,300,468 Read SEC document |
| September 07, 2022 Filed Sep 7, 2022 21:45 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 6,000 | $2.58 | $15,480.00 |
DisclosureSEC source: 0001209191-22-049055 · doc4.xml · nonDerivative · entry 2 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,296,468 Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 21:45 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 4,000 | $2.55 | $10,200.00 |
DisclosureSEC source: 0001209191-22-049055 · doc4.xml · nonDerivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,290,468 Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 21:16 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 1,520 | $2.19 | $3,325.76 |
DisclosureSEC source: 0001209191-22-036395 · doc4.xml · nonDerivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,286,468 F1 · price: The range of prices for the shares of Common Stock is from $2.115 to $2.2301. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| June 09, 2022 Filed Jun 9, 2022 21:59 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 2,000 | $2.25 | $4,490.00 |
DisclosureSEC source: 0001209191-22-035554 · doc4.xml · nonDerivative · entry 2 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,284,948 F1 · price: The range of prices for the shares of Common Stock is from $2.24 to $2.25. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:59 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 1,000 | $2.31 | $2,310.00 |
DisclosureSEC source: 0001209191-22-035554 · doc4.xml · nonDerivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,282,948 Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 21:44 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantStock Option (Right to Buy) · Derivative | 800,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-055525 · doc4.xml · derivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2031-09-07 F1 · derivative.exercise_date: The option will vest as follows: 20% will vest on September 8, 2022, 20% will vest on September 8, 2023, 25% will vest on September 8, 2024 and 35% will vest on September 8, 2025. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 22:15 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 3,830 | $3.93 | $15,070.28 |
DisclosureSEC source: 0001209191-21-054545 · doc4.xml · nonDerivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,277,948 F1 · price: The range of prices for the shares of Common Stock is from $3.91 to $3.97. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| August 31, 2021 Filed Oct 7, 2021 23:18 UTC Amendment | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 5,830 | $3.94 | $22,970.20 |
DisclosureSEC source: 0001209191-21-059989 · doc4a.xml · nonDerivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,281,948 F1 · price: The range of prices for the shares of Common Stock is from $3.91 to $3.97. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| August 30, 2021 Filed Aug 30, 2021 23:41 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 6,000 | $3.93 | $23,599.80 |
DisclosureSEC source: 0001209191-21-053958 · doc4.xml · nonDerivative · entry 3 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,274,118 F3 · price: The range of prices for the shares of Common Stock is from $3.91 to $3.96. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 23:41 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 6,000 | $3.77 | $22,620.00 |
DisclosureSEC source: 0001209191-21-053958 · doc4.xml · nonDerivative · entry 2 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,268,118 F2 · price: The range of prices for the shares of Common Stock is from $3.74 to $3.83. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| August 27, 2021 Filed Oct 7, 2021 23:17 UTC Amendment | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 8,000 | $3.76 | $30,100.00 |
DisclosureSEC source: 0001209191-21-059988 · doc4a.xml · nonDerivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,270,118 F1 · price: The range of prices for the shares of Common Stock is from $3.74 to $3.83. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 23:41 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 6,500 | $3.84 | $24,969.75 |
DisclosureSEC source: 0001209191-21-053958 · doc4.xml · nonDerivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,262,118 F1 · price: The range of prices for the shares of Common Stock is from $3.80 to $3.89. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| July 22, 2021 Filed Jul 23, 2021 23:04 UTC | HCW Biologics Inc. HCWB · Entity 8172 | ConversionSeries C Redeemable Preferred Stock · Derivative | 1,071,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048063 · doc4.xml · derivative · entry 7 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,071,428 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of the Series C Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F3 · shares: Represents shares received upon the conversion of shares of Series C Redeemable Convertible Preferred Stock. All shares were purchased jointly by Hing C. Wong and Bee Yau Huang. F7 · derivative.exercise_date: Each share of the Series C Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F7 · derivative.expiration_date: Each share of the Series C Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. Read SEC document |
| July 22, 2021 Filed Jul 23, 2021 23:04 UTC | HCW Biologics Inc. HCWB · Entity 8172 | ConversionSeries B Redeemable Preferred Stock · Derivative | 2,954,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048063 · doc4.xml · derivative · entry 6 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,954,285 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of the Series B Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F2 · shares: Represents shares received upon the conversion of shares of Series B Redeemable Convertible Preferred Stock. Includes 1,525,714 shares purchased jointly by Hing C. Wong and Bee Yau Huang. F6 · derivative.exercise_date: Each share of the Series B Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F6 · derivative.expiration_date: Each share of the Series B Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. Read SEC document |
| July 22, 2021 Filed Jul 23, 2021 23:04 UTC | HCW Biologics Inc. HCWB · Entity 8172 | ConversionSeries A Redeemable Preferred Stock · Derivative | 6,316,691 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048063 · doc4.xml · derivative · entry 5 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,316,691 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the Series A Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F1 · shares: Represents shares received upon the conversion of shares of Series A Redeemable Convertible Preferred Stock. Includes 902,977 shares purchased jointly by Hing C. Wong and Bee Yau Huang. F5 · derivative.exercise_date: Each share of the Series A Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F5 · derivative.expiration_date: Each share of the Series A Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. Read SEC document |
| July 22, 2021 Filed Jul 23, 2021 23:04 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 627,500 | $8.00 | $5,020,000.00 |
DisclosureSEC source: 0001209191-21-048063 · doc4.xml · nonDerivative · entry 4 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,255,618 F3 · shares: Represents shares received upon the conversion of shares of Series C Redeemable Convertible Preferred Stock. All shares were purchased jointly by Hing C. Wong and Bee Yau Huang. F4 · shares: Represents shares of Common Stock purchased in connection with the Issuer's initial public offering for consideration of $8.00 per share. Read SEC document |
| July 22, 2021 Filed Jul 23, 2021 23:04 UTC | HCW Biologics Inc. HCWB · Entity 8172 | ConversionCommon Stock | 1,071,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048063 · doc4.xml · nonDerivative · entry 3 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,628,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents shares received upon the conversion of shares of Series C Redeemable Convertible Preferred Stock. All shares were purchased jointly by Hing C. Wong and Bee Yau Huang. Read SEC document |
| July 22, 2021 Filed Jul 23, 2021 23:04 UTC | HCW Biologics Inc. HCWB · Entity 8172 | ConversionCommon Stock | 2,954,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048063 · doc4.xml · nonDerivative · entry 2 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,556,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents shares received upon the conversion of shares of Series B Redeemable Convertible Preferred Stock. Includes 1,525,714 shares purchased jointly by Hing C. Wong and Bee Yau Huang. Read SEC document |
| July 22, 2021 Filed Jul 23, 2021 23:04 UTC | HCW Biologics Inc. HCWB · Entity 8172 | ConversionCommon Stock | 6,316,691 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048063 · doc4.xml · nonDerivative · entry 1 Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,602,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares received upon the conversion of shares of Series A Redeemable Convertible Preferred Stock. Includes 902,977 shares purchased jointly by Hing C. Wong and Bee Yau Huang. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.